Media and Communications

News

2004 News Releases

Tuesday, December 21, 2004
Teva Board Of Directors Increases Repurchase Program To Up To $600 Million Of Teva Securities

Jerusalem, Israel, December 21, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that its Board of Directors has increased its repurchase program to authorize the Company to purchase up to an aggregate of $600 million of Teva securities, up from the $300 million previously authorized on September 3, 2004. The authorized amount includes approximately $180 million expended under the previous authorization on Teva's ADRs, ordinary shares and convertible debentures. Under the program, Teva, through one or more of its subsidiaries, may repurchase its ordinary shares/ADRs an Read More »

Tuesday, December 21, 2004
Teva Announces Tentative Approval Of Rosiglitazone Maleate Tablets

Jerusalem, Israel, December 21, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the company's ANDA for Rosiglitazone Maleate Tablets, 2 mg, 4 mg and 8 mg. Final approval is expected upon the resolution of patent litigation.Teva's Rosiglitazone Maleate Tablets are the AB-rated generic equivalent of SB Pharmaco's Avandia® Tablets. This product is indicated as an adjunct to diet and exercise in the treatment of type 2 diabetes.The brand product has annual sales of approximately $1.4 billion.Tev Read More »

Thursday, December 16, 2004
Teva Launches Quinapril Hcl Tablets; Pursuant To Agreement With Ranbaxy

Jerusalem, Israel, December 16, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Ranbaxy Pharmaceuticals Inc. announced today that Teva has begun commercially shipping Quinapril HCl Tablets, 5 mg, 10 mg, 20 mg and 40 mg, manufactured pursuant to Ranbaxy's ANDA No. 076607, which received final FDA approval. The product will be sold under the Teva label and marketed by Teva USA.Quinapril HCl Tablets are the AB-rated generic equivalent of Parke Davis' antihypertensive agent Accupril® Tablets. The brand product has annual sales of approximately $555 million.Teva is distributing the pr Read More »

Wednesday, December 15, 2004
Teva Announces Approval And Launch Of Gabapentin Tablets

Jerusalem, Israel, December 15, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Gabapentin Tablets, 600 mg and 800 mg. Shipment of this product has commenced.Gabapentin Tablets are the AB-rated generic equivalent of Pfizer's anticonvulsant, Neurontin® Tablets, which had annual sales of approximately $1.05 billion for the twelve months ended September 2004.Teva's launch follows Alpharma's recent introduction of Gabapentin Tablets. The companies will share Alpharma's 180-day Read More »

Tuesday, December 14, 2004
Teva Announces Tentative Approval Of Metformin Hcl Extended Release Tablets, 750 Mg

Jerusalem, Israel, December 14, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's ANDA for Metformin Hydrochloride Extended Release Tablets, 750 mg. Final approval is anticipated upon the expiration of any relevant exclusivity period.Teva's Metformin HCl ER Tablets, 750 mg, are the AB-rated generic equivalent of Bristol-Myers Squibb's Glucophage® XR Tablets, 750 mg, a product indicated for the treatment of type 2 diabetes.The brand product has annual sales of approximately $27 mi Read More »

Friday, December 10, 2004
Teva Announces Tentative Approval Of Oxycodone Hydrochloride Er Tablets, 10 Mg, 20 Mg, And 40 Mg

Jerusalem, Israel, December 10, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's ANDA for Oxycodone Hydrochloride Extended Release Tablets, 10 mg, 20 mg, and 40 mg. Final approval is subject to the expiration of any applicable exclusivity period enjoyed by another ANDA filer for the same product. Oxycodone Hydrochloride Tablets are the AB-rated generic equivalent of Purdue Pharma's OxyContin® Controlled Release Tablets. The product is indicated for the management of moderate to Read More »

Wednesday, December 01, 2004
Teva Closes Acquisition Of Pfizer's Italian Generic Pharmaceutical Operation - Dorom

Jerusalem, Israel, December 1, 2004 - Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today, further to its announcement dated August 17, 2004, that it has completed its cash acquisition, of Pfizer's Italian generic pharmaceutical marketing company, Dorom S.r.l., one of the largest suppliers of generic pharmaceuticals to the Italian retail market.Teva Italy will integrate Dorom's business into its own pharmaceutical activities and will actively promote the product lines of both companies.Subsequent to this acquisition, Teva, which is the largest generic company in Italy, will furt Read More »

Tuesday, November 30, 2004
Teva Announces Promotions and Additions to its Management Team

Jerusalem, Israel, November 30, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today a number of management promotions, as well as the addition of new executive talent to its management team. These appointments are part of the continuing process of development of management capacity designed to keep pace with rapid growth.Mr. William Fletcher, currently President and CEO - Teva North America, will assume a new role as Chairman - Teva North America. Mr. George Barrett, currently President and CEO of Teva Pharmaceuticals USA, will be promoted to the position of President and Read More »

Wednesday, November 24, 2004
Teva Announces Approval Of Cilostazol Tablets

Jerusalem, Israel, November 24, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Cilostazol Tablets, 50 mg and 100 mg. Shipment of this product is expected to begin immediately.Teva's Cilostazol Tablets are the AB-rated generic equivalent of Otsuka's Pletal® Tablets, a product indicated for treatment of intermittent claudication.The brand product has annual sales of approximately $178 million.Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 25 Read More »

Sunday, November 21, 2004
Teva Announces Tentative Approval Of Fosphenytoin Sodium Injection

Jerusalem, Israel, November 21, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's ANDA for Fosphenytoin Sodium Injection USP, 50 mg PE/mL (PE = phenytoin sodium equivalents). Final approval is expected upon patent expiry on August 5, 2007.Teva's Fosphenytoin Sodium Injection is the AP-rated generic equivalent of Pfizer's anticonvulsant Cerebyx® Injection.The brand product has annual sales of approximately $62 million.Teva Pharmaceutical Industries Ltd., headquartered in Israel, i Read More »

​​​